The trial was designed to evaluate the therapy’s efficacy and safety in treating AML, as well as myelodysplastic syndromes.

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount ...

New service ensures rapid delivery of small volume clinical trial materials, solving a critical bottleneck in drug ...